Adaptive Biotechnologies Delivers Breakout Quarter as clonoSEQ Volumes Surge and MRD Becomes a Drug Development Standard
Q1 2026 Earnings Call, May 5, 2026 — MRD revenue up 53%, guidance raised, and first primary endpoint milestone recognized
Adaptive Biotechnologies emerged from its first quarter earnings call with a notably stronger growth profile than investors had anticipated entering the year. The company raised full-year MRD revenue guidance to $260 million to $270 million, up from a prior range of $255 million to $265 million, and lifted its clinical volume growth expectation to at least 35% for 2026, having already met its original full-year community mix target in just one quarter. The story is no longer about whether clonoSEQ can scale — it is about how quickly the broader diagnostics and drug development ecosystem is organizing itself around the platform.
Clinical Volume Growth Accelerates Beyond Expectations
clonoSEQ tests reached a quarterly record of nearly 32,600 in Q1, up 41% year-over-year and 9% sequentially, ahead of what the company had guided entering the year. DLBCL led the sequential charge at over 19% quarter-on-quarter growth, a figure that drew immediate analyst attention given the competitive noise in that indication. Management was direct about the durability of that growth: the gains reflect embedded advantages in brand recognition, assay sensitivity and specificity, and real-world clinical experience rather than any one-time conference-driven tailwind. As CEO Chad Robins noted, "it's really early days for MRD and DLBCL in general," and the commercial team expects multiple quarters of strong growth ahead as physicians continue integrating MRD into routine practice.
The number of ordering clinicians grew 43% year-over-year to nearly 5,000, a metric that captures the breadth of institutional acceptance. U.S. average selling price rose 11% year-over-year to $1,360 per test, and the company remains on track for approximately $1,400 per test by year-end, supported by Medicaid expansion, commercial payer negotiations, and recent policy updates in CLL and DLBCL. Notably, clonoSEQ is now listed in the Texas Medicaid policy manual, one of only two specific tests included in the state's newly developed genetic testing section, with coverage of up to six tests per year.
Community Setting and EMR Integration Are Compounding Each Other
Community volumes grew 67% year-over-year and now represent 35% of total testing, already at the company's stated full-year target. The character of the commercial conversation in community oncology has meaningfully shifted. As Chief Commercial Officer Susan Bobulsky described it, discussions have moved from "what is MRD, why should I care?" to practical implementation: standardizing testing protocols across large community networks and ensuring that hematology patients are not missed by generalist oncologists who see a diverse patient mix daily. "That sort of practical implementation-oriented conversation is more and more of the norm," she said, "and I think a really positive sign for the degree to which MRD is now becoming really entrenched as part of the standard of care."
The EMR integration strategy is accelerating the conversion of community access into repeat utilization. Six new Epic accounts have been added year-to-date, with five more expected to go live within the next month. Adaptive is now integrated with seven of its top ten academic accounts. For Flatiron-integrated community practices, 72% of repeat orders due are being fulfilled — a pull-through rate that management describes as improving. With approximately 150 community accounts on EMR integrations, the company's current focus is not adding accounts but optimizing existing ones, deploying what Robins called "a very strong playbook" to drive serial monitoring adoption within integrated practices.
Blood-Based Testing Rises as a Structural Growth Driver
Blood-based testing reached 49% of total MRD volume in Q1, rapidly approaching the company's full-year target of greater than 50%. The more strategically significant data point is in multiple myeloma, a historically bone marrow-driven indication, where blood-based MRD now represents 29% of testing, up 8 percentage points year-over-year. This shift matters not just for patient convenience but because increased blood utilization correlates with higher testing frequency, expanding the total addressable volume per patient. The migration toward blood-based protocols in the community setting is closely linked to simplified ordering dynamics and the practical reality that peripheral blood draws are more feasible in non-academic environments.
First Primary Endpoint Milestone Is a Signal, Not Just Revenue
Adaptive recognized its first U.S. MRD primary endpoint milestone in Q1, tied to the CEPHEUS trial in multiple myeloma. The $9 million in milestone revenue is excluded from the company's forward guidance — management has stated it does not anticipate additional milestone revenue for the remainder of 2026 — but the strategic significance extends well beyond the dollar amount. The company now has 23 active studies where MRD is being used as a primary endpoint, out of 111 total primary and secondary endpoint studies across an active portfolio of approximately 190 trials. The milestone validates clonoSEQ's role not as a supporting biomarker but as a registrational-grade endpoint capable of determining trial success or failure.
The biopharma backlog reached approximately $254 million, up 24% year-over-year, with bookings driven primarily by regulated studies including several registrational trials across multiple myeloma and CLL. In Q1 alone, 10 new registrational studies were signed, already exceeding the company's full-year goal for new registrational bookings. Pharma MRD revenue grew 53% year-over-year, or 33% excluding the milestone. While management is holding pharma revenue guidance at approximately 11% to 12% year-over-year growth for the full year — a deliberately conservative stance given quarter-to-quarter lumpiness — the trajectory of bookings and backlog conversion suggests meaningful upside potential in the second half.
Regulatory Tailwinds From FDA's New Clinical Trial Model
Adaptive highlighted an emerging regulatory dynamic that could structurally expand the pharma MRD opportunity. The FDA has introduced a new clinical trial model incorporating real-time data submission, with the TrAVeRse trial in mantle cell lymphoma as an early proof-of-concept study, using MRD-negative complete response as measured by clonoSEQ as a key endpoint. Management characterized this model as reinforcing the value of endpoints that are "objective, quantitative and longitudinal" — attributes that favor clonoSEQ's design relative to less standardized alternatives. The company is also seeing approximately 20 ongoing interventional studies where MRD is used for enrollment, stratification, or to guide therapy decisions, a use case that only works reliably with an assay that offers the high sensitivity and specificity Adaptive claims for clonoSEQ.
The companion diagnostic question surfaced during Q&A. Bobulsky acknowledged that some future studies may position MRD explicitly as a companion diagnostic, but noted that to date the FDA has not required that framing. Regardless of regulatory classification, she emphasized that biopharma partners are already actively approaching Adaptive to discuss how to maximize MRD adoption in support of their own therapies — a dynamic that blurs the line between clinical diagnostics partner and commercial co-promotion.
Margin Expansion Is Real and Accelerating
Sequencing gross margin reached 70% in Q1, up 8 percentage points year-over-year, driven by efficiencies from the NovaSeq X platform launched in the second half of 2025 and operating leverage on higher volumes. The MRD segment posted adjusted EBITDA of $12.1 million, compared to a loss of $4.1 million in the prior year period. CFO Kyle Piskel described 75% sequencing gross margin as the "North Star" for the year, with a roughly linear step-up expected through year-end as volume compounds and pricing improves. Total company adjusted EBITDA was a loss of $2.5 million for the quarter, and the company remains on track to achieve positive adjusted EBITDA and positive free cash flow at the total company level by year-end 2026.
Cash ended the quarter at approximately $222 million, with the Immune Medicine segment running at an adjusted EBITDA loss of $10.4 million, within the guided $15 million to $20 million full-year cash burn range for that segment. Total operating expenses of $90.1 million were up 10% year-over-year, with roughly 75% of spend allocated to MRD, 20% to Immune Medicine, and the remainder to corporate costs.
PAMA and Reimbursement Risk: Management Pushes Back Firmly
The question of Medicare reimbursement risk under the CRUSH initiative and potential PAMA reporting requirements drew a detailed response from Robins. The company's position, supported by outside counsel, is that clonoSEQ is currently not subject to PAMA reporting requirements for the current cycle. The reasoning hinges on two statutory criteria: a test must fall under the Clinical Lab Fee Schedule and must account for more than 50% of Medicare revenue. CMS does not list the MolDX billing code used for clonoSEQ's episodic rate structure on the CLFS. The PLA code used for mantle cell lymphoma recurrence monitoring does appear on the CLFS, but revenues generated under that code remain well below the 50% threshold. Separately, Adaptive is in discussions with MolDX to increase the number of tests per bundle under the episode structure — a potential positive for per-patient economics — though Robins declined to speculate on timing given the unpredictability of government contractor and agency processes.
Immune Medicine: Steady Execution, Limited Near-Term Catalysts
Immune Medicine revenue was $3.8 million in Q1, down 26% year-over-year due to timing of sample receipts and processing rather than any structural deterioration. The company now has more than 6 million functional TCR-antigen pairs spanning approximately 50,000 antigens and 50-plus HLA types, and recently published work confirming its digital AI model outperforms public benchmarks in predicting TCR-antigen binding. The Pfizer partnership for rheumatoid arthritis target discovery kicked off this quarter, with over 1,000 patient samples received and a data package targeted for delivery in the second half of 2026. Management described the segment as operating within its guided cash burn envelope, with additional data partnerships under discussion, but offered no near-term catalysts that would meaningfully alter the investment calculus for this part of the business.
Commercial Infrastructure: Steady State, Not Expansion Mode
Adaptive's commercial organization currently consists of 65 sales representatives, split evenly between academic account managers and community-focused diagnostic hematology specialists. Management indicated no plans for significant headcount expansion in 2026, instead directing incremental investment toward EMR integration, reimbursement and revenue cycle management, and clinical data generation. The strategic logic is clear: with community contribution already at full-year targets and EMR integrations compounding serial order utilization, the returns on optimizing existing infrastructure currently exceed those from adding new feet on the street.
Adaptive Biotechnologies Corporation Deep Dive
Decoding the Adaptive Immune System
In the rapidly evolving landscape of precision oncology, the ability to measure minimal residual disease has transitioned from a theoretical research endpoint to an indispensable clinical tool. Adaptive Biotechnologies Corporation operates at the vanguard of this paradigm shift. While the broader liquid biopsy market has fixated on tracking somatic mutations in solid tumors, Adaptive has cornered the market for hematological malignancies. The company harnesses the inherent biology of the adaptive immune system, utilizing high-throughput next-generation sequencing to map the unique genetic barcodes of T-cell and B-cell receptors. This platform serves as the foundation for the company's dual-engine business model, structurally separated to balance aggressive commercial growth in diagnostics with high-upside optionality in drug discovery. As the clinical consensus solidifies around minimal residual disease as the ultimate arbiter of treatment efficacy, Adaptive's underlying sequencing architecture has established a formidable moat in blood cancer management.
Business Model and Revenue Generation
Following a pivotal strategic review and corporate restructuring in April 2024, Adaptive Biotechnologies operates two distinct business segments: Minimal Residual Disease and Immune Medicine. The restructuring deliberately insulated the high-growth, cash-generating Minimal Residual Disease business from the heavier research and development burn of the Immune Medicine pipeline, a move that fundamentally altered the financial trajectory of the company. Today, the Minimal Residual Disease segment accounts for approximately 95 percent of total revenues and serves as the primary engine for margin expansion.
Adaptive monetizes its Minimal Residual Disease segment through its flagship diagnostic assay, clonoSEQ. The revenue stream here is bifurcated into clinical testing and biopharmaceutical partnerships. On the clinical side, oncologists order the test to establish a baseline genetic profile of a patient's lymphoid cancer, followed by serial monitoring tests to detect residual cancer cells during and after therapy. Adaptive bills third-party payers, Medicare, and patients directly for these assays. On the biopharma side, the company partners with pharmaceutical manufacturers who embed clonoSEQ into their clinical trials as a primary or secondary endpoint to measure drug efficacy. These pharmaceutical agreements generate testing revenue as well as highly accretive regulatory milestone payments, such as the $9 million recognized in the first quarter of 2026 for primary endpoint achievements. The dual nature of this segment ensures that Adaptive captures value both during the development of novel cancer therapies and subsequently during their commercial clinical rollout.
The Immune Medicine segment monetizes Adaptive's vast proprietary database of immune receptor data. Rather than selling diagnostic tests, this division engages in target discovery and data licensing agreements. By mapping how T-cell receptors bind to specific disease antigens, Adaptive can identify autoreactive receptors responsible for autoimmune conditions or protective receptors against specific pathogens. The company generates revenue in this segment through upfront licensing fees, data delivery fees, and downstream clinical and commercial milestones. While revenue in this segment experienced a structural decline following the full amortization of legacy agreements, the underlying intellectual property remains a call option on future therapeutic discoveries.
The Competitive Landscape and Market Share
The minimal residual disease testing market is broadly divided by tumor biology, creating a stark competitive dichotomy. In the solid tumor space, companies like Natera, Guardant Health, and Exact Sciences engage in fierce competition, utilizing circulating tumor DNA to track colorectal, breast, and lung cancers. However, Adaptive Biotechnologies operates in an almost parallel monopoly within hematological malignancies, including multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. Because blood cancers are fundamentally diseases of the immune system, tracking them requires sequencing the highly variable V(D)J recombination regions of immune cells rather than looking for standard somatic mutations. Adaptive's sequencing platform was purpose-built for this biological reality, effectively insulating it from the price wars and platform substitution risks seen in the solid tumor liquid biopsy market.
Within its hematological niche, Adaptive's market share is dominant. While laboratory-developed tests and flow cytometry remain legacy alternatives, they lack the rigorous standardization and scale of clonoSEQ. Competitors such as Invivoscribe offer commercially available next-generation sequencing assays like LymphoTrack, which hospital laboratories can perform in-house. However, these distributed assays face significant hurdles in achieving uniform reimbursement and matching the logistical ease of a centralized, broadly FDA-cleared test. Adaptive's volume metrics illustrate this dominance; the company delivered nearly 105,600 clonoSEQ tests in 2025 and accelerated to over 32,500 tests in the first quarter of 2026 alone, driven by adoption across both major academic medical centers and an expanding footprint in the community oncology setting.
Moats and Competitive Advantages
Adaptive's most formidable competitive advantage is its regulatory moat. clonoSEQ holds the unique distinction of being the first and only FDA-cleared in vitro diagnostic for tracking minimal residual disease in multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia. This regulatory seal of approval is paramount in oncology, fundamentally shifting the conversation with both ordering physicians and commercial payers. Consequently, Adaptive has secured coverage for over 300 million lives across Medicare and virtually every major private insurer in the United States. This reimbursement density ensures that over 90 percent of patients pay zero dollars out of pocket, removing the primary friction point for serial diagnostic testing.
The company also benefits from profound technological and data-scale advantages. The clonoSEQ assay achieves a remarkable sensitivity threshold of detecting a single cancer cell among one million healthy cells. This 10^-6 sensitivity consistently outperforms standard multiparametric flow cytometry. Furthermore, Adaptive's deep integration into clinical guidelines cements its status as the standard of care. National Comprehensive Cancer Network guidelines specifically reference the use of highly sensitive next-generation sequencing assays to guide treatment duration in chronic lymphocytic leukemia and other indications, practically mandating clonoSEQ utilization for compliance with best practices.
Finally, Adaptive enjoys a structural gross margin advantage derived from its centralized laboratory model and technological scale. By transitioning to higher-throughput sequencing platforms like the NovaSeq X+, the company has driven sequencing gross margins to 70 percent as of early 2026. Rather than undertaking the capital-intensive process of building owned laboratories abroad, Adaptive utilizes an asset-light technology transfer model for international expansion, partnering with local laboratories while maintaining strict control over the bioinformatic analysis and data generation.
Industry Dynamics: Opportunities and Threats
The foremost opportunity for Adaptive lies in the evolution of minimal residual disease testing from a purely prognostic indicator to an interventional necessity. Historically, clinicians used minimal residual disease status merely to inform patients of their relapse risk. Today, the treatment paradigm is shifting towards dynamic, biology-driven intervention. Landmark clinical data, such as the EndRAD study in pediatric leukemia, demonstrated that patients achieving minimal residual disease negativity can safely forego highly toxic total body irradiation prior to stem cell transplants without compromising survival. As more data readouts validate the cessation of expensive and toxic therapies for minimal residual disease-negative patients, commercial payers and clinicians will increasingly view clonoSEQ not as an added diagnostic cost, but as a mandatory tool to optimize treatment duration and generate systemic healthcare savings.
Another major structural tailwind is the transition from bone marrow aspirates to peripheral blood-based testing. Historically, monitoring blood cancers required deeply invasive and painful bone marrow biopsies, which severely limited patient compliance with serial testing protocols. Adaptive's optimization of clonoSEQ for blood-based sample types has unlocked the serial monitoring market. As of the first quarter of 2026, roughly 49 percent of all clonoSEQ tests were performed using peripheral blood. This shift creates a compounding, recurring revenue stream as a single patient baseline generates multiple follow-up testing orders over several years of surveillance.
The primary threats to Adaptive's trajectory are macroeconomic constraints on healthcare utilization and the theoretical convergence of solid tumor diagnostic platforms into the hematological space. While the biological barriers to entry are exceptionally high, well-capitalized players in the circulating tumor DNA space continuously seek to expand their total addressable market. Furthermore, hospital budgets and reimbursement environments are perpetually under pressure. However, the embedded nature of clonoSEQ within FDA labels and pharmaceutical clinical trial protocols provides a strong bulwark against immediate product substitution or pricing degradation.
New Technologies and Future Growth Drivers
While the Minimal Residual Disease segment provides the financial bedrock, Adaptive's Immune Medicine platform represents significant long-term optionality. The company's ability to decode the T-cell receptor repertoire allows it to identify the specific immune cells responsible for driving autoimmune diseases. This capability transitions Adaptive from a pure oncology diagnostic company into a discovery engine for immunology therapeutics.
A prime example of this technological leverage is the non-exclusive agreement signed with Pfizer in late 2025. Under this partnership, Adaptive is utilizing its immune medicine platform to identify autoreactive T-cell receptors that drive rheumatoid arthritis, discovering novel therapeutic targets. The financial structure of this agreement highlights the latent value of the platform, featuring an upfront payment and potential downstream development and commercial milestones totaling nearly $890 million. By identifying disease-causing receptors with pinpoint accuracy, Adaptive is positioning itself as a vital foundational layer for the next generation of targeted autoimmune therapies, entirely divorced from the competitive pressures of the oncology testing market.
Management Track Record and Execution
The narrative surrounding Adaptive's management over the last few years is one of necessary rationalization and rigorous execution. Prior to 2024, the company struggled with a bloated cost structure, attempting to aggressively fund both a sprawling diagnostic commercial rollout and highly speculative therapeutic discovery programs simultaneously. Under the leadership of CEO Chad Robins and the financial discipline introduced by CFO Kyle Piskel, the executive team executed a masterclass in strategic refocusing. By concluding the April 2024 strategic review with a mandate to operate the segments independently, management structurally halted the cash burn that had historically alienated institutional investors.
The execution of this pivot has been clinically precise. Management successfully guided the Minimal Residual Disease segment to adjusted EBITDA profitability in the second half of 2025. Entering 2026, the operational leverage is glaringly apparent; in the first quarter of 2026, total revenue grew 45 percent year-over-year to $70.9 million, obliterating consensus estimates, while cash burn was reduced by 77 percent. The company's balance sheet remains fortress-like, with over $237 million in cash equivalents bridging them comfortably to their stated target of whole-company positive adjusted EBITDA and free cash flow generation by the end of 2026. Management's recent decision to raise full-year 2026 Minimal Residual Disease revenue guidance to $260 million to $270 million reflects a high degree of forward visibility and operational confidence.
The Scorecard
Adaptive Biotechnologies has successfully navigated the difficult transition from a cash-burning genomics pioneer to a financially disciplined, commercially dominant diagnostic leader. The company possesses an effective monopoly in the hematological minimal residual disease market, protected by an impenetrable web of FDA clearances, deep clinical guideline integration, and universally established payer reimbursement. The ongoing shift toward blood-based serial monitoring is transforming the company's revenue profile into a highly predictable, recurring stream, while the transition to higher-throughput sequencing hardware is aggressively expanding gross margins toward an elite diagnostic tier.
Beyond the core diagnostic franchise, the structurally separated Immune Medicine segment provides a free call option on massive therapeutic markets, validated by blue-chip pharmaceutical partnerships. Management has proven its ability to make difficult capital allocation decisions, right-sizing the expense base and providing a clear, fully funded runway to enterprise-wide profitability. By dominating its biological niche and executing with clinical precision, the company is poised to capture the long-term compounding value of precision immune profiling.